Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells

Prostate

Volumn 28, Issue 3, 1996, Pages 172-181

  Cronauer, Marcus V ^a   Klocker, Helmut ^a   Talasz, Heribert ^b   Geisen, Francoise H ^b   Hobisch, Alfred ^a   Radmayr, Christian ^a   Böck, Günther ^b   Culig, Zoran ^a   Schirmer, Michael ^b   Reissigl, Andreas ^a   Bartsch, Georg ^a   Konwalinka, Günther ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

advanced prostate cancer; antimetabolite of pyrimidine metabolism; granulopoietic macrophagic progenitor cells; prostate cancer cell lines

Indexed keywords

DEOXYCYTIDINE; GEMCITABINE; NUCLEOSIDE ANALOG;

ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CARCINOMA CELL; CELL PROLIFERATION; COLONY FORMING UNIT GM; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL CYCLE; CELL DIVISION; DEOXYCYTIDINE; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 13344270904     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(199603)28:3<172::AID-PROS4>3.0.CO;2-H     Document Type: Article

References (30)

1. Delong DC, Hertel LW, Tang J, Kroin JS, Wilson JD, Terry J, Lavender JF: Antiviral acvtivity of 2′, 2′-difluorodeoxycytidine. Am Soc Microbiol Abstracts, 1986.
2. Gridney GB, Boder GB, Hertel LW, Kroin JS, Poore GA, Rinzel SM, Todd GC: Antitumor activity of 2′, 2′-difluorodeoxycytidine (LY188011). Proc Am Assoc Cancer Res 27:296, 1986. (Abstract)
3. Ban J, Weber G: Synergistic action of tiazofurin and difluorodeoxycytidine on differentiation and cytotoxicity. Biochem Biophys Res Commun 184:551-559, 1992.
4. Boven E, Schipper H, Erkelens CAM, Hatty SA, Pinedo HM: The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br J Cancer 68:52-56, 1993.
5. Braakhuis BJM, van Dogen GAMS, Vermorken JB, Snow GB: Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res 51:211-214, 1991.
6. Kaye SB: Gemcitabine: current status of phase I and II trials. J Clin Oncol 10:1527-1531, 1994.
7. Lund B, Kristjansen PEG, Hansen HH: Clinical and preclinical activity of 2′, 2′-difluorodeoxycytidine (gemcitabine) Cancer Treat Rev 19:45-55, 1993.
8. Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W: Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10:406-413, 1992.
9. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, Plunkett W: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498, 1991.
10. Morgan-Ihrig C, Lembersky B, Christopherson W, Tarassoff P: A phase II evaluation of difluorodeoxycytidine (dFdC) in advanced stage refractory ovarian cancer. Proc Am Soc Clin Oncol 10:196, 1991. (Abstract)
11. Lund B, Hansen OP, Neijt JP, Stroier I, Hansen M: Phase II study of gemcitabine in previously treated ovarian cancer patients. Proc Am Soc Clin Oncol 11: 222, 1992. (Abstract)
12. Singhal RL, Yeh YA, Szekeres T, Weber G: Increased deoxycytidine kinase activity in cancer cells and inhibition by difluorodeoxycytidine. Oncol Res 4:517-522, 1992.
13. Ruiz-van-Haperen VWT, Veerman G, Vermorken JB, Peters GJ: 2′,2′-difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol 46:762-766, 1993.
14. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110-6117, 1991.
15. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17:16-23, 1979.
16. Stone KR, Mickey DH, Wunderli H, Mickey GH, Paulson DF: Isolation of a human prostate carcinoma cell line (DU-145). Int J Cancer 21:274-281, 1978.
17. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LN-CaP model of human prostatic carcinoma. Cancer Res 43:1809-1818, 1983.
18. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63, 1983.
19. Park J-G, Kramer BS, Steinberg SM, Carmichael J, Collins JM, Minna JD, Gazdar AF: Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay. Cancer Res 47: 5875-5879, 1987.
20. Taylor IW: A rapid single step staining technique for DNA analysis by flow microfluorimetry. J Histochem Cytochem 28:1021-1024, 1980.
21. Shapiro HM: "Practical Flow Cytometry." New York: Alan R. Liss, 1988.
22. Petzer AL, Bilgeri R, Zilian U, Haun M, Geisen FH, Pragnell I, Braunsteiner H, Konwalinka G: Inhibitory effect of 2-chlorodeoxyadenosine on granulocytic, erythroid and T-lymphocytic colony growth. Blood 78: 2583-2587, 1991.
23. Peehl DM, Wong ST, Stamey TA: Cytostatic effects of suramin on prostate cancer cells cultured from primary tumors. J Urol 145:624-630, 1991.
24. Stearns ME, Wang M: Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. Cancer Res 52:3776-3781, 1992.
25. Ewing MW, Liu SC, Gnarra JR, Walther MM, Meyers CE, Linehan WM: Effect of suramin on the mitogenic response of the human prostate carcinoma cell line PC-3. Cancer (Suppl) 71:1151-1158, 1993.
26. De Coster R, Wouters W, Van Ginckel R, End D, Krekels M, Coene MC, Bowden C: Experimental studies with Liarozole (R 75 251) an antitumoral agent which inhibits retinoic acid breakdown. J Steroid Biochem Molec Biol 43:197-201, 1992.
27. Myers C, Cooper M, Stein C, LaRocca R, Walther MM, Weiss G, Choyke P, Dawson N, Steinberg S, Uhrich MM, Cassidy J, Kohler DR, Trepel J, Linehan WM: Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 10:881-889, 1992.
28. Pienta KJ, Nguyen NM, Lehr JE: Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res 53:224-226, 1993.
29. Weber G: Biochemical strategy of cancer cells and the design of chemotherapy: G.H.A. Clowes Memorial Lecture. Cancer Res 43:3466-3492, 1983.
30. Carson DA, Wasson DB, Taetle R, Yu A: Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 62:737-743, 1983.